Thursday, September 21, 2017
=BioCryst (BCRX),: RAPIVAB receives FDA approval for a pediatric indication
BioCryst Pharma announces FDA approval of a sNDA for RAPIVAB (peramivir injection), extending its availability for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment